Document is current

Any future updates will be listed below

Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation

Crossref DOI link: https://doi.org/10.1038/s41409-021-01507-3

Published Online: 2021-10-28

Published Print: 2022-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark